MONDAY, Oct. 21, 2019 (HealthDay News) -- Boosting exercise capacity may protect the mental functioning of childhood leukemia survivors, according to a new study.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Due to their disease and treatment, childhood ALL survivors are at increased risk for problems with thinking and memory, as well as reduced exercise cap...
WEDNESDAY, Aug. 21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
A drug called selinexor appeared to help patients with the blood and bone marrow cancer, according to a clinical trial involving 122 people.
THURSDAY, Aug. 8, 2019 (HealthDay News) -- If a close relative has had blood cancer, you're more likely to get it, a large new study reports.
The researchers analyzed data from 16 million people in Sweden, including more than 153,000 diagnosed with blood cancer and more than 391,000 of their first-degree relatives: parents, siblings or children.
WEDNESDAY, July 3, 2019 (HealthDay News) -- More than 8.7 million years of life and about $94 billion in earnings were lost to cancer in the United States in 2015, researchers say.
Cancer is the nation's second-leading killer and is expected to cause nearly 607,000 deaths this year. These premature deaths and the lost productivity they cause impose a significant economic burden, the s...
WEDNESDAY, March 27, 2019 (HealthDay News) -- The chances of finding an unrelated bone marrow donor are higher for U.S. patients of European descent than for those of non-European descent, a new study finds.
A bone marrow transplant can sometimes help people with life-threatening blood cancers by replacing the patient's cells with healthy ones from a donor. A brother or sister with th...
MONDAY, May 7, 2018 (HealthDay News) -- Generic drugs tend to trigger big drops in the cost of their expensive, brand-name counterparts, but that has not been the case with the cancer drug commonly known as Gleevec (imatinib).
There's been only a small drop in the price of imatinib since a generic version was introduced to compete with Gleevec, a new study finds.